Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic Renal cell carcinoma

Cancer Immunology Research

Volumn 3, Issue 9, 2015, Pages 1017-1029

  Liu, Xian De ^a   Hoang, Anh ^a   Zhou, Lijun ^a   Kalra, Sarathi ^a   Yetil, Alper ^a   Sun, Mianen ^a   Ding, Zhiyong ^a   Zhang, Xuesong ^a   Bai, Shanshan ^a   German, Peter ^a   Tamboli, Pheroze ^a   Rao, Priya ^a   Karam, Jose A ^a   Wood, Christopher ^a   Matin, Surena ^a   Zurita, Amado ^a   Bex, Axel ^b   Griffioen, Arjan W ^c   Gao, Jianjun ^a   Sharma, Padmanee ^a   Tannir, Nizar ^a   Sircar, Kanishka ^a   Jonasch, Eric ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; PROGRAMMED DEATH 1 LIGAND 1; SUNITINIB; TRANSCRIPTION FACTOR FOXP3; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CD274 PROTEIN, HUMAN; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER IMMUNOLOGY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; KIDNEY METASTASIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CARCINOMA, RENAL CELL; DRUG EFFECTS; DRUG RESISTANCE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; KIDNEY NEOPLASMS; NUDE MOUSE; SECONDARY; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL CULTURE; UPREGULATION; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; BEVACIZUMAB; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG RESISTANCE, NEOPLASM; HETEROGRAFTS; HUMANS; IMMUNE TOLERANCE; INDOLES; KIDNEY NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE, NUDE; NEOPLASM TRANSPLANTATION; PYRROLES; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT; UP-REGULATION;

EID: 84962013731     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0244     Document Type: Article

References (46)

1. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12:298-306.
2. Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, et al. Proliferative activity of intratumoral CD8 (+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001;61:5132-6.
3. Bromwich EJ, McArdle PA, Canna K, McMillan DC, McNicol AM, Brown M, et al. The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer 2003;89:1906-8.
4. Siddiqui SA, Frigola X, Bonne-Annee S, Mercader M, Kuntz SM, Krambeck AE, et al. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res 2007;13:2075-81.
5. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
6. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
7. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008;8:523-32.
8. Brugarolas J. Renal-cell carcinoma-molecular pathways and therapies. N Engl J Med 2007;356:185-7.
9. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
10. Gunturi A, McDermott DF. Potential of new therapies like anti-PD1 in kidney cancer. Curr Treat Options Oncol 2014;15:137-46.
11. Ribas A, Tumeh PC. The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade. Clin Cancer Res 2014;20:4982-4.
12. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.
13. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515:558-62.
14. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-7.
15. Liu XD, Ko S, Xu Y, Fattah EA, Xiang Q, Jagannath C, et al. Transient aggregation of ubiquitinated proteins is a cytosolic unfolded protein response to inflammation and endoplasmic reticulum stress. J Biol Chem 2012;287:19687-98.
16. Kim J, Jonasch E, Alexander A, Short JD, Cai S, Wen S, et al. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res 2009;15:81-90.
17. Liu XD, Yao J, Tripathi DN, Ding Z, Xu Y, Sun M, et al. Autophagy mediates HIF2a degradation and suppresses renal tumorigenesis. Oncogene 2015;34:2450-60.
18. Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol 2010;11:373-82.
19. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GMCSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006;116:1935-45.
20. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 2008;105:14987-92.
21. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Upregulation of PD-L1, IDO, and T (regs) in the melanoma tumor microenvironment is driven by CD8 (+) T cells. Sci Transl Med 2013;5:200ra116.
22. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127ra137.
23. Guleria I, Sayegh MH. Maternal acceptance of the fetus: true human tolerance. J Immunol 2007;178:3345-51.
24. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004;101:17174-9.
25. Su SC, Hu X, Kenney PA, Merrill MM, Babaian KN, Zhang XY, et al. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma. Clin Cancer Res 2013;19:6461-72.
26. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1a, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 2014;211:781-90.
27. Dings RP, Vang KB, Castermans K, Popescu F, Zhang Y, Oude Egbrink MG, et al. Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer. Clin Cancer Res 2011;17:3134-45.
28. Farsaci B, Higgins JP, Hodge JW. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer 2012;130:1948-59.
29. Dirkx AE, oude Egbrink MG, Castermans K, van der Schaft DW, Thijssen VL, Dings RP, et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J 2006;20:621-30.
30. Bellone M, Calcinotto A. Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front Oncol 2013;3:231.
31. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011;334:1573-7.
32. Griffioen AW, Damen CA, Blijham GH, Groenewegen G. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 1996;88:667-73.
33. Griffioen AW, Damen CA, Martinotti S, Blijham GH, Groenewegen G. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res 1996;56:1111-7.
34. Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini BI, et al. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer 2011;129:2158-70.
35. Zhao Y, Xue T, Yang X, Zhu H, Ding X, Lou L, et al. Autophagy plays an important role in sunitinib-mediated cell death in H9c2 cardiac muscle cells. Toxicol Appl Pharmacol 2010;248:20-7.
36. Guo XL, Li D, Sun K, Wang J, Liu Y, Song JR, et al. Inhibition of autophagy enhances anticancer effects of bevacizumab in hepatocarcinoma. J Mol Med (Berl) 2013;91:473-83.
37. Huang H, Langenkamp E, Georganaki M, Loskog A, Fuchs PF, Dieterich LC, et al. VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-kB-induced endothelial activation. FASEB J 2015;29:227-38.
38. Zhang Y, Lu Y, Ma L, Cao X, Xiao J, Chen J, et al. Activation of vascular endothelial growth factor receptor-3 in macrophages restrains TLR4-NFkappaB signaling and protects against endotoxin shock. Immunity 2014;40:501-14.
39. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patientswith metastatic renal cell carcinoma. JClin Oncol 2009;27:3584-90.
40. Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009;69:2514-22.
41. Herrmann A, Kortylewski M, Kujawski M, Zhang C, Reckamp K, Armstrong B, et al. Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res 2010;70:7455-64.
42. Dannenmann SR, Thielicke J, Stockli M, Matter C, von Boehmer L, Cecconi V, et al. Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology 2013;2:e23562.
43. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006;24:677-88.
44. deLeeuw RJ, Kroeger DR, Kost SE, Chang PP, Webb JR, Nelson BH. CD25 identifies a subset of CD4+FoxP3-TIL that are exhausted yet prognostically favorable in human ovarian cancer. Cancer Immunol Res 2015;3:245-53.
45. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014;124:687-95.
46. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014;74:5458-68.